Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 8/20 | 0.41 |
| ▸ | CALCR | P30988 | 8/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | GIPR | P48546 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 7/20 | 0.41 |
| ▸ | NPY4R | P50391 | 7/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.41 |
| ▸ | NPY1R | P25929 | 5/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422395 | 0.92 | GRB2 (0.44) | GRB2RAMP3CALCRAPLNR | |
| SCHEMBL29468872 | 0.92 | GRB2 (0.40) | GRB2GLP1RGCGRGIPRNPY1R | |
| SCHEMBL30423238 | 0.88 | GRB2 (0.46) | GRB2RAMP3CALCR | |
| SCHEMBL30744330 | 0.84 | GRB2 (0.41) | GRB2GLP1RGCGRGIPRAPLNR | |
| SCHEMBL30543476 | 0.83 | GRB2 (0.44) | GRB2GLP1RGCGRGIPRAPLNR | |
| SCHEMBL29468889 | 0.83 | GRB2 (0.42) | GRB2APLNR | |
| SCHEMBL30744292 | 0.82 | APLNR (0.42) | GRB2GLP1RGCGRGIPRAPLNR | |
| SCHEMBL38651991 | 0.82 | APLNR (0.43) | GRB2GLP1RGCGRGIPRAPLNR | |
| SCHEMBL31197908 | 0.82 | APLNR (0.44) | GRB2GLP1RGCGRGIPRAPLNR | |
| SCHEMBL29760938 | 0.81 | GRB2 (0.41) | GRB2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| EP-4146248-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | GRB2 524/4885RAMP3 2750/4885CALCR 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.